First Impact Factor for : Endocrine, Metabolic & Immune Disorders - Drug Targets
News release date: June 23, 2016
Dubai, UAE, June 23, 2016: Endocrine, Metabolic & Immune Disorders - Drug Targets has obtained its first Impact Factor 1.987. The Impact Factor ranking has been awarded by Journal Citation Reports®, which are annually published by the Institute of Scientific Information, a division of Thomson Reuters. Its purpose is to offer a systematic means to critically evaluate the world's leading journals, with quantifiable, statistical information based on citation data.